DX5 Stock Overview
A medical device company, provides blood volume measurement technology focused on blood volume testing. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Daxor Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.25 |
| 52 Week High | US$9.50 |
| 52 Week Low | US$6.45 |
| Beta | -0.54 |
| 11 Month Change | 0.61% |
| 3 Month Change | 11.49% |
| 1 Year Change | 21.32% |
| 33 Year Change | -16.67% |
| 5 Year Change | n/a |
| Change since IPO | 0.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| DX5 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 3.8% | -2.2% | -0.2% |
| 1Y | 21.3% | -6.1% | 7.8% |
Return vs Industry: DX5 exceeded the German Medical Equipment industry which returned -6.1% over the past year.
Return vs Market: DX5 exceeded the German Market which returned 7.8% over the past year.
Price Volatility
| DX5 volatility | |
|---|---|
| DX5 Average Weekly Movement | 11.6% |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DX5's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DX5's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | n/a | Michael Feldschuh | www.daxor.com |
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.
Daxor Corporation Fundamentals Summary
| DX5 fundamental statistics | |
|---|---|
| Market cap | €41.10m |
| Earnings (TTM) | €1.59m |
| Revenue (TTM) | €145.65k |
25.8x
P/E Ratio282.2x
P/S RatioIs DX5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DX5 income statement (TTM) | |
|---|---|
| Revenue | US$154.21k |
| Cost of Revenue | US$0 |
| Gross Profit | US$154.21k |
| Other Expenses | -US$1.53m |
| Earnings | US$1.69m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | 1,094.00% |
| Debt/Equity Ratio | 5.1% |
How did DX5 perform over the long term?
See historical performance and comparison